Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10593
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCharles, Patrick G P-
dc.contributor.authorWhitby, Michael-
dc.contributor.authorFuller, Andrew J-
dc.contributor.authorStirling, Robert-
dc.contributor.authorWright, Alistair A-
dc.contributor.authorKorman, Tony M-
dc.contributor.authorHolmes, Peter W-
dc.contributor.authorChristiansen, Keryn J-
dc.contributor.authorWaterer, Grant W-
dc.contributor.authorPierce, Robert J-
dc.contributor.authorMayall, Barrie C-
dc.contributor.authorArmstrong, John G-
dc.contributor.authorCatton, Michael G-
dc.contributor.authorNimmo, Graeme R-
dc.contributor.authorJohnson, Barbara-
dc.contributor.authorHooy, Michelle-
dc.contributor.authorGrayson, M Lindsay-
dc.date.accessioned2015-05-16T00:06:05Z
dc.date.available2015-05-16T00:06:05Z
dc.date.issued2008-05-15-
dc.identifier.citationClinical Infectious Diseases; 46(10): 1513-21en_US
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10593en
dc.description.abstractAvailable data on the etiology of community-acquired pneumonia (CAP) in Australia are very limited. Local treatment guidelines promote the use of combination therapy with agents such as penicillin or amoxycillin combined with either doxycycline or a macrolide.The Australian CAP Study (ACAPS) was a prospective, multicenter study of 885 episodes of CAP in which all patients underwent detailed assessment for bacterial and viral pathogens (cultures, urinary antigen testing, serological methods, and polymerase chain reaction). Antibiotic agents and relevant clinical outcomes were recorded.The etiology was identified in 404 (45.6%) of 885 episodes, with the most frequent causes being Streptococcus pneumoniae (14%), Mycoplasma pneumoniae (9%), and respiratory viruses (15%; influenza, picornavirus, respiratory syncytial virus, parainfluenza virus, and adenovirus). Antibiotic-resistant pathogens were rare: only 5.4% of patients had an infection for which therapy with penicillin plus doxycycline would potentially fail. Concordance with local antibiotic recommendations was high (82.4%), with the most commonly prescribed regimens being a penicillin plus either doxycycline or a macrolide (55.8%) or ceftriaxone plus either doxycycline or a macrolide (36.8%). The 30-day mortality rate was 5.6% (50 of 885 episodes), and mechanical ventilation or vasopressor support were required in 94 episodes (10.6%). Outcomes were not compromised by receipt of narrower-spectrum beta-lactams, and they did not differ on the basis of whether a pathogen was identified.The vast majority of patients with CAP can be treated successfully with narrow-spectrum beta-lactam treatment, such as penicillin combined with doxycycline or a macrolide. Greater use of such therapy could potentially reduce the emergence of antibiotic resistance among common bacterial pathogens.en_US
dc.language.isoenen
dc.subject.otherAdolescenten
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAnti-Bacterial Agents.therapeutic useen
dc.subject.otherAustralia.epidemiologyen
dc.subject.otherBacteria.drug effects.isolation & purificationen
dc.subject.otherCeftriaxone.therapeutic useen
dc.subject.otherCommunity-Acquired Infections.epidemiology.microbiology.mortality.virologyen
dc.subject.otherDoxycycline.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherGuideline Adherence.statistics & numerical dataen
dc.subject.otherHumansen
dc.subject.otherMacrolides.therapeutic useen
dc.subject.otherMaleen
dc.subject.otherMicrobial Sensitivity Testsen
dc.subject.otherMiddle Ageden
dc.subject.otherPenicillins.therapeutic useen
dc.subject.otherPneumonia, Bacterial.epidemiology.microbiology.mortalityen
dc.subject.otherPneumonia, Viral.epidemiology.mortality.virologyen
dc.subject.otherProspective Studiesen
dc.subject.otherTreatment Outcomeen
dc.subject.otherViruses.isolation & purificationen
dc.titleThe etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical Infectious Diseasesen_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.doi10.1086/586749en_US
dc.description.pages1513-21en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/18419484en
dc.contributor.corpauthorAustralian CAP Study Collaborationen
dc.type.contentTexten_US
dc.type.austinJournal Articleen
local.name.researcherCharles, Patrick G P
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptInfectious Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

72
checked on Dec 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.